Mirae Asset Global Investments Co. Ltd. Has $253,000 Holdings in Jazz Pharmaceuticals PLC $JAZZ

Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 17.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,382 shares of the specialty pharmaceutical company’s stock after buying an additional 350 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Jazz Pharmaceuticals were worth $253,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of JAZZ. Platinum Investment Management Ltd. raised its position in shares of Jazz Pharmaceuticals by 13.9% during the 2nd quarter. Platinum Investment Management Ltd. now owns 2,355 shares of the specialty pharmaceutical company’s stock valued at $250,000 after acquiring an additional 287 shares during the last quarter. Philip James Wealth Mangement LLC boosted its position in shares of Jazz Pharmaceuticals by 42.0% in the 2nd quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company’s stock worth $1,676,000 after purchasing an additional 4,675 shares during the last quarter. Truist Financial Corp boosted its position in shares of Jazz Pharmaceuticals by 0.5% in the 2nd quarter. Truist Financial Corp now owns 32,751 shares of the specialty pharmaceutical company’s stock worth $3,476,000 after purchasing an additional 148 shares during the last quarter. XML Financial LLC boosted its position in shares of Jazz Pharmaceuticals by 44.6% in the 2nd quarter. XML Financial LLC now owns 3,926 shares of the specialty pharmaceutical company’s stock worth $417,000 after purchasing an additional 1,210 shares during the last quarter. Finally, Kendall Capital Management boosted its position in shares of Jazz Pharmaceuticals by 3.3% in the 2nd quarter. Kendall Capital Management now owns 8,229 shares of the specialty pharmaceutical company’s stock worth $873,000 after purchasing an additional 265 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total transaction of $771,720.00. Following the transaction, the director owned 429,973 shares of the company’s stock, valued at $55,303,127.26. The trade was a 1.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $135.43 on Friday. The company has a market capitalization of $8.22 billion, a PE ratio of -20.12, a price-to-earnings-growth ratio of 8.32 and a beta of 0.28. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The firm’s 50 day moving average is $125.87 and its 200-day moving average is $115.65. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same quarter in the prior year, the company earned $5.30 earnings per share. The company’s quarterly revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. The Goldman Sachs Group increased their target price on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research note on Friday, August 29th. Zacks Research raised Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Deutsche Bank Aktiengesellschaft started coverage on shares of Jazz Pharmaceuticals in a report on Tuesday, July 15th. They set a “buy” rating and a $152.00 price objective for the company. Truist Financial boosted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Finally, Royal Bank Of Canada lifted their price target on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an “outperform” rating in a research report on Thursday, August 28th. Fourteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $178.93.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.